Trials / Completed
CompletedNCT01367574
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
A Phase II Double-Blind, Randomized, Parallel Group, Dose Ranging Study of Subcutaneous Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous methylnaltrexone to be conducted in patients with advanced medical illness and poorly controlled opioid induced constipation. Patients will be randomized to one of three fixed dose levels of SC MNTX.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SC MNTX | Dose 1 |
| DRUG | SC MNTX | Dose 2 |
| DRUG | SC MNTX | Dose 3 |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2003-05-01
- Completion
- 2003-05-01
- First posted
- 2011-06-07
- Last updated
- 2019-11-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01367574. Inclusion in this directory is not an endorsement.